“Today’s announcement is important as it offers some clarity to the EMA staff and their families about their futures. I hope the move to Amsterdam is carried out as smoothly as possible to make the transition easier for those people and to ensure the important work of the EMA can continue.
“I hope now that the future location of the EMA is settled, attention can now be turned to the critical issues surrounding the UK’s future relationship with the EU and future participation in regulatory structures and processes. PAGB believes that mutual recognition agreements between the EMA and the Medicines and Healthcare products Regulatory Agency (MHRA) should be put in place to avoid any unnecessary duplication between the two agencies. We also believe the UK should remain part of the EU pharmacovigilance and surveillance systems to protect public health. These and other important issues need to be discussed and agreed as early as possible.”
